|
BOD1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.66453525910038E-15 |
| Normal-vs-Stage2 |
3.58039999870385E-08 |
| Normal-vs-Stage3 |
2.65343302885412E-14 |
| Normal-vs-Stage4 |
8.71414052028285E-13 |
| Stage1-vs-Stage2 |
9.963800E-01 |
| Stage1-vs-Stage3 |
1.230610E-01 |
| Stage1-vs-Stage4 |
5.091900E-02 |
| Stage2-vs-Stage3 |
3.091800E-01 |
| Stage2-vs-Stage4 |
1.205020E-01 |
| Stage3-vs-Stage4 |
4.759000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.77847999999203E-05 |
| Normal-vs-Asian |
1.07380000446966E-08 |
| Caucasian-vs-AfricanAmerican |
5.457400E-01 |
| Caucasian-vs-Asian |
6.657000E-01 |
| AfricanAmerican-vs-Asian |
7.983800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.04054608952265E-13 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.147750E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.01205718752817E-12 |
| Normal-vs-Age(41-60Yrs) |
1.77635683940025E-15 |
| Normal-vs-Age(61-80Yrs) |
1.64035451888367E-12 |
| Normal-vs-Age(81-100Yrs) |
1.161610E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.771200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.059180E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.977400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.909400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.687000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.228800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.427800E-02 |
| Classical-VS-Follicular |
5.447800E-02 |
| Classical-VS-Other |
1.617150E-01 |
| Classical-VS-Normal |
8.65239990766042E-10 |
| Tall-VS-Follicular |
4.607600E-01 |
| Tall-VS-Other |
6.723000E-01 |
| Tall-VS-Normal |
3.62599950065601E-11 |
| Follicular-VS-Other |
5.079000E-01 |
| Follicular-VS-Normal |
5.09481346000484E-12 |
| Other-VS-Normal |
2.818200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.99760216648792E-15 |
| Normal-vs-N1 |
1.55360169173946E-11 |
| N0-vs-N1 |
3.576400E-01 |
|
|
